Afrin Moisturizing Nasal Spray for Rhinitis, 15 ml, Bayer
Category
Runny nose
Scope of the medicinal product
Ear, Throat, Nose
Release form
Spray
Manufacturer country
Canada
Package quantity, pcs
one
Dosage form
Nasal spray: a white or almost white gel-like suspension with a characteristic citrus odor.
Structure
Active ingredient: oxymetazoline hydrochloride 0.5 mg.
Nasal spray
Excipients: microcrystalline cellulose and sodium carmellose (Avicel RC-591) 30 mg, sodium hydrogen phosphate 0.975 mg, sodium dihydrogen phosphate monohydrate 5.525 mg, disodium edetate dihydrate 0.3 mg, macrogol-1450 50 mg, povidone-K29-32 30 mg, benzyl alcohol 2.5 mg, lemon flavor 1.5 mg, benzalkonium chloride solution 17% 1.471 mg, glycerol 5 mg, purified water qs up to 1 ml.
pharmachologic effect
Topical alpha adrenergic stimulant.
Has a vasoconstrictor effect.
Oxymetazoline causes vasoconstriction of the mucous membranes of the nose, paranasal sinuses and the Eustachian tube, which leads to a decrease in their edema and the release of nasal breathing in allergic and / or infectious-inflammatory rhinitis (rhinitis).
Due to the presence in the composition of the drug of excipients (microcrystalline cellulose and carmellose sodium and povidone-K29-32) AfrinВ® moisturizing nasal spray does not flow out of the nose and does not flow down the throat, since after being introduced into the nasal passages, the spray becomes more viscous and retains more effective on nasal mucous membranes than standard aqueous solution.
This drug contains moisturizers (glycerol and macrogol-1450) to help retain moisture, which helps keep dry or irritated nasal mucosa moisturized.
According to clinical studies, the drug begins to act within 1 minute and lasts up to 12 hours.
Pharmacokinetics
When used as a nasal spray, oxymetazoline is practically not detected in blood plasma.
Side effects
In general, the drug is well tolerated, and possible adverse events are usually mild and transient.
Transient dryness and burning of the nasal mucosa, dry mouth and throat, sneezing
increased blood pressure, increased anxiety, nausea, dizziness, headache, insomnia, palpitations, sleep disturbances.
With prolonged use - tachyphylaxis, reactive hyperemia and atrophy of the nasal mucosa.
Benzalkonium chloride, which is part of the drug, can cause local skin reactions.
Selling features
Available without a prescription
Special conditions
With prolonged use (more than one week), the symptoms of nasal congestion may recur.
If it is necessary to continue treatment for more than 5 days, a consultation with a doctor is required.
Avoid getting the drug in the eyes.
The drug, when used correctly and in recommended doses, does not affect driving vehicles and working with mechanisms, however, if side effects such as dizziness occur, you should refrain from these activities.
Application during pregnancy and lactation
The safety of the drug in pregnant women and during lactation has not been established, therefore, the drug should be prescribed to pregnant or breastfeeding women only on the recommendation of a doctor if the expected benefit from using the drug for the mother outweighs the potential risk to the fetus or infant.
Indications
Difficulty in nasal breathing with colds, sinus inflammation, eustachitis, hay fever, allergic rhinitis, congestion and conjunctival edema
Contraindications
Hypersensitivity to sympathomimetic drugs, to any component of the drug, atrophic rhinitis, simultaneous use of monoamine oxidase inhibitors (including a period of 14 days after their cancellation), children under 6 years of age.
Carefully
Coronary artery disease, arrhythmias, chronic cardiac weeks
Name ENG
AFRIN MOISTURIZING
Clinical and pharmacological group
A vasoconstrictor drug for local use in ENT practice
ATX code
Oxymetazoline
Dosage
0.05% x 15ml
Structure
Active ingredient: oxymetazoline hydrochloride 0.5 mg.
Excipients: microcrystalline cellulose and sodium carmellose (Avicel RC-591) 30 mg, sodium hydrogen phosphate 0.975 mg, sodium dihydrogen phosphate monohydrate 5.525 mg, disodium edetate dihydrate 0.3 mg, macrogol-1450 50 mg, povidone-K29-32 30 mg, benzyl alcohol 2.5 mg, lemon flavor 1.5 mg, benzalkonium chloride solution 17% 1.471 mg, glycerol 5 mg, purified water qs up to 1 ml.
Indications
Symptomatic therapy of rhinitis (rhinitis) of allergic and / or infectious-inflammatory etiology
sinusitis
eustachitis
hay fever.
INN / Active ingredient
Oxymetazoline
Contraindications
Atrophic rhinitis
simultaneous use of MAO inhibitors (including a period of 14 days after their cancellation)
children under 6 years of age.
hypersensitivity to drug components
hypersensitivity to sympathomimetic drugs.,
With care: coronary artery disease, arrhythmias, chronic heart failure, severe atherosclerosis, arterial hypertension, hyperthyroidism, diabetes mellitus, chronic renal failure, angle-closure glaucoma, prostatic hyperplasia with clinical symptoms, pregnancy, lactation.
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 2 years
Specifications
Category
Runny nose
Scope of the medicinal product
Ear, Throat, Nose
Release form
Spray
Manufacturer country
Canada
Package quantity, pcs
one
Scope of application
Virology
Minimum age from
6 years
Way of introduction
On the mucous membrane
Vacation conditions
Without recipe
Volume, ml.
15 ml
Brand name
Afrin
The amount of the dosage form in the primary package
15 ml
Primary packaging type
Polyethylene bottle with a dosing device
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Decongestant - alpha adrenergic agonist
Anatomical and therapeutic characteristics
R01AA05 Oxymetazoline
Dosage form
Nasal spray
The target audience
Children
Dosage (volume) of the substance in the preparation
1 ml - 0.5 mg
Expiration date in days
730
Package weight, g
15
Mode of application
:
Intranasal. < br> < br> Shake the spray bottle vigorously before each use. children over 6 years old - 2-3 injections into each nasal passage with an interval of 10-12 hours.
The frequency of use can be increased up to 3 times a day in adults.
It is not recommended to exceed the indicated dose.
Information on technical characteristics, delivery set, country of manufacture